US Patent 9,649,456 (Migraine powdered sumatriptan delivered to posterior nasal cavity using exhaled bi-directional air flow): Scope, claim coverage, and US patent landscape
Executive summary
US 9,649,456 is a US method-and-device patent anchored on a specific intranasal delivery mode for migraine: powdered sumatriptan (consisting essentially of sumatriptan succinate in the key independent claim) is delivered to the posterior nasal cavity using exhaled air that (i) closes the oropharyngeal velum via a mouthpiece, and (ii) creates a bi-directional flow through the nasal cavity via a nosepiece and an inlet/outlet connected to a container chamber that entrains the powder. Claim scope is concentrated around: (1) no introduced excipients/adjuvants, (2) narrow bulk density windows, (3) defined particle size distributions, (4) posterior deposition by nasal-valve obstruction/expansion features, (5) quantified nasal absorption fraction vs total BA ratios, and (6) inhalation/timing PK targets. Downstream freedom-to-operate risk is driven by whether a product uses the same entrainment-and-bi-directional-flow mechanism, the same “consists essentially of” restriction, and overlapping particle/bulk density ranges.
What is US Patent 9,649,456 claiming and what is the core invention?
Answer: It claims methods of treating migraine by delivering powdered sumatriptan to the posterior region of the nasal cavity using a mouthpiece + nosepiece system in which the patient’s exhalation closes the oropharyngeal velum to generate bi-directional airflow through the nasal cavity, entraining powder from a container chamber via an inlet/outlet arrangement, with powder defined by “consists essentially of sumatriptan succinate without introduced excipients or adjuvants” plus specific bulk density and particle size distributions.
Independent claim 1: method coverage (highly specific delivery mechanics + powder specs)
Claim 1’s coverage combines five technical pillars:
-
Therapy endpoint
- Treat migraine in a human by delivering powdered sumatriptan to the posterior nasal cavity.
-
Patient-actuated airflow control
- Insert nosepiece into nasal cavity.
- Insert mouthpiece into mouth.
- Subject exhales through mouthpiece, causing closure of oropharyngeal velum.
- Mouthpiece is fluidly connected to nosepiece.
- Exhaled air is delivered through the nosepiece.
-
Entrained powder delivery via bi-directional flow
- Powder is delivered through nosepiece to posterior nasal region “via a bi-directional flow through the nasal cavity.”
- Powder originates from a container chamber housing a container with powder.
- Chamber has an inlet connected to mouthpiece and an outlet connected to nosepiece.
- Exhalation acts to entrain powder and deliver it through nosepiece.
-
Composition restriction
- Powdered substance consists essentially of sumatriptan succinate.
- No introduced excipients or adjuvants.
-
Powder physical property windows (tight claim hooks)
- Untapped bulk density: 0.3 to 0.5 g/mL
- Particle size distribution:
- 10% less than ~20 µm
- 50% less than ~50 µm
- 90% less than ~150 µm
Dependent claims 2–14: narrowing into capsule form, nasal valve control, PK/BA ratios
Key narrowing features include:
-
Capsule container materials (claim 2):
- Capsule formed from cellulose derivatives, HPMC, or gelatin derivatives.
-
Nasal valve engineering (claims 3–4):
- Nosepiece extends into nasal valve and provides expansion, or
- Nosepiece obstructs/closes nasal valve to prevent anterior deposition.
-
Tapped bulk density (claim 5):
-
Dose (claim 6):
-
Nasal absorption fraction / total BA ratio thresholds (claims 7–9):
-
Powder density point-values (claims 10–11):
- Untapped bulk density about 0.4 g/mL
- Tapped bulk density about 0.63 g/mL
-
Capsule piercing (claim 12):
- Piercing the capsule before delivery
-
Alternative detailed plasma PK target (claim 14):
- Tmax < 25 minutes and Cmax ≥ 10 ng/mL
Claim 15 (and 23) re-state a broadly similar “mouthpiece + nosepiece + bi-directional air flow” frame with different particle distribution language
Claims 15 and 23 recast the concept as delivering powdered sumatriptan substance to posterior nasal region, using:
- Nosepiece into nostril
- Mouthpiece into mouth (for claims that include mouthpiece)
- Velum closure by exhalation
- Bi-directional air flow entraining powder
- Powder parameters:
- Untapped bulk density: 0.3 to 0.5 g/mL
- Particle size distribution: “50% greater than about 30 µm” (note the claim wording is unusual; as written it implies a median >30 µm rather than ≤30 µm)
Claims 16–18/20–21/24–25 etc. then add powder identity options and “no introduced excipients/adjuvants” limitations.
Device claims 31, 39: system coverage for equipment, not just use
Device claim 31 covers:
- Nosepiece configured to fit nostril
- Substance containing unit connected to nosepiece
- Powder in a defined density and particle range
- Device configuration that oral exhalation through the unit + nosepiece closes velum and produces a bi-directional exhalation flow into one nasal passage and out the other, delivering powder posteriorly.
Device claim 39 adds a mouthpiece plus nosepiece plus connected substance unit, with the exhalation air flow entraining powder and passing into one nasal passage and out of the other.
What patentable matter is the “consists essentially of” restriction doing?
Answer: It creates a composition fence. Claim 1 requires that the powdered substance “consists essentially of sumatriptan succinate without introduced excipients or adjuvants.” That language is stronger than “substantially free of excipients” because it targets introduced third-party components.
Practical claim consequence
- A competitor powder that uses any introduced excipients/adjuvants (e.g., carriers, dispersants, surfactants, stabilizers) would have a colorable argument of non-infringement if the only permitted constituents are limited to sumatriptan succinate plus inherent/trace impurities.
- The device/method claims that include the “only sumatriptan succinate and no introduced excipients or adjuvants” dependent language similarly narrow risk for products using engineered excipient-free powders.
How do the bulk density and particle size distribution limitations affect infringement risk?
Answer: They provide numeric technical thresholds that can be used in claim construction and product testing.
Untapped bulk density window (primary)
- Claim 1: 0.3–0.5 g/mL (untapped)
- Device claim 31: 0.3–0.5 g/mL
- Claims 15/23: 0.3–0.5 g/mL
Particle size distribution buckets
- Claim 1: 10% <20 µm, 50% <50 µm, 90% <150 µm
- Claims 15/23: “50% greater than about 30 µm”
- Claims 22/30/38/46: 90% greater than about 10 µm and 10% greater than about 90 µm (as written, this is also directionally unusual; it reads as “% greater than,” which would mean most particles exceed those cutoffs)
Litigation-relevant testing points
- Whether a product meets these distributions is likely to require:
- method-of-measure specification (laser diffraction vs sieving vs microscopy)
- sampling representativeness
- batch-to-batch variability
- For FTO and litigation, these parameters are among the first things to line up with product CoA and lab characterization data.
Which claim elements most strongly distinguish this from prior intranasal sumatriptan products?
Answer: The “mouthpiece + velum closure + inlet/outlet container chamber + bi-directional airflow entrainment + posterior deposition” combination is the core distinguishing structure, layered with powder-spec numeric thresholds and excipient-free “consists essentially of” composition.
Distinctive feature clusters in the claims
-
Bi-directional airflow created by velum closure
- Exhalation through a mouthpiece closes oropharyngeal velum and drives airflow through nasal passages in both directions (into one and out of the other).
-
Container chamber inlet/outlet linked to airflow pathway
- Powder entrained from a chamber with inlet (mouthpiece) and outlet (nosepiece).
-
Posterior delivery via nasal valve control
- Nosepiece expansion/obstruction features in claims 3–4 to prevent anterior deposition.
-
Excipients disallowed (in key phrasing)
- “consists essentially of sumatriptan succinate without introduced excipients/adjuvants.”
-
Powder physical specs
- Bulk density and PSD ranges that likely correlate to aerosolization and deposition.
What is the US exclusivity and expiration timeline for US 9,649,456?
Answer: Not enough information is provided to accurately determine filing date, priority date, prosecution history, PTA, or potential patent term adjustment for US 9,649,456. Without those inputs, an exclusivity and expiration timeline cannot be computed.
How does US 9,649,456 fit into the migraine sumatriptan intranasal patent landscape?
Answer: It targets intranasal delivery of sumatriptan powders using patient exhalation to entrain dry powder and drive posterior deposition. The relevant landscape includes:
- prior art intranasal sumatriptan formulations (sprays/solutions)
- device-based dry powder inhalation systems
- any prior excipient-free or PSD-defined powdered APIs
- any prior nasal delivery approaches aiming for posterior nasal deposition or nasal-valve management.
Claim-to-landscape mapping (what to search for in competitor estates)
For freedom-to-operate and enforcement, search for US family members and nearby patents covering:
- Dry powder intranasal sumatriptan (API form, salt form, PSD, density)
- Nasal deposition enhancement via nasal-valve sealing, obstruction, or airflow redirection
- Exhalation-driven dosing mechanisms (mouthpiece + nasal outlet; entrainment chamber with inlet/outlet)
- Capsule/ piercing mechanisms linked to nasal powder delivery
- PK targets and nasal absorption fraction/BA ratio claims (method claims often include in vivo performance constraints)
What Orange Book status exists for sumatriptan intranasal products, and does it relate to this patent?
Answer: Not enough information is provided here to map US 9,649,456 to specific Orange Book listings, listed active ingredients, listed dosage forms, or Orange Book code(s). Without product-identification and patent listing details, an Orange Book status determination cannot be made.
What Paragraph IV or generic entry risks exist for this patent?
Answer: This cannot be determined from the provided information alone because it requires:
- identification of the Orange Book-listed drug tied to the patent family
- whether any ANDA/505(b)(2) exists for the relevant dosage form
- whether US 9,649,456 is listed in the Orange Book for that drug
- whether any litigations or settlements have been filed and their dates/case numbers.
How strong is the patent estate for US 9,649,456 based on claim structure?
Answer: Strength is mixed: the independent method claim is narrow in delivery mechanics and powder parameters, but that narrowness can be a litigation lever if accused products match the airflow mechanism and powder specs.
Strength factors
- Multiple conjunctive limitations in claim 1:
- mouthpiece + velum closure + fluid connection
- bi-directional flow through nasal cavity
- chamber inlet/outlet entrainment
- excipient-free “consists essentially of” salt
- tight bulk density + PSD bands
- That makes non-infringement easier if any one of those is missing or materially different.
- But if an accused product is essentially the same dosing system with similar powder characteristics, infringement arguments can be direct.
Weakness factors / design-around pathways
- Excipients/adjuvants:
- Any introduced excipient/adjuvant may be a clean route around the “consists essentially of” limitation (subject to claim construction).
- Powder specs:
- Changing PSD or bulk density outside claim windows may avoid literal infringement.
- Mechanism changes:
- Using a different airflow generation mechanism (e.g., external compressed air, mechanical insufflation, pressure-driven spray, or different entrainment architecture) can break the “bi-directional exhalation flow” requirement.
- Posterior deposition via nasal valve management:
- If a device does not expand/obstruct the nasal valve as claimed, it may still avoid infringement depending on whether claims require those features in the independent claim (claim 1 does not require claims 3–4; they are dependent).
Claim chart style comparison: what must a suspected product do to infringe?
Answer: A competent infringement analysis would map these elements. Below is an element checklist derived from claim 1 and core device claims.
| Claim element |
What accused product must have |
| Treat migraine |
Indication/use tied to migraine |
| Powder to posterior nasal cavity |
Delivery location is posterior nasal region |
| Mouthpiece + velum closure by exhalation |
Patient exhales through a mouthpiece; mechanism causes velum closure |
| Fluid connection mouthpiece to nosepiece |
System connects oral and nasal flow pathways |
| Bi-directional airflow through nasal cavity |
Air flows into one nasal passage and out the other (not simply one-direction insufflation) |
| Powder entrained from chamber with inlet/outlet |
Powder housed in chamber with inlet connected to mouthpiece and outlet connected to nosepiece |
| “Consists essentially of sumatriptan succinate” (no introduced excipients) |
Powder composition restricted to sumatriptan succinate only (plus allowable impurities) |
| Untapped bulk density 0.3–0.5 g/mL |
Powder meets bulk density window |
| PSD thresholds |
PSD meets 10% <20 µm; 50% <50 µm; 90% <150 µm |
Device claims lower the threshold to system components and their configured airflow behavior, but still keep density and PSD limitations.
What formulations are protected by US 9,649,456?
Answer: The claims primarily protect an excipient-free powder of sumatriptan succinate with specific physical property windows. The patent is not a typical “formulation patent” in the sense of describing excipient mixtures; it is a dry powder specification patent coupled to a mechanical delivery system.
Composition scope inside the claims
- Primary: sumatriptan succinate powder
- Dependent variants: sumatriptan base or succinate appear in later claims (15/16/23/24), but the strongest limitation set is “only sumatriptan succinate and no introduced excipients/adjuvants” in dependent claims (e.g., 17 and 25 for those recast claims).
What method-of-use and device features are protected beyond powder composition?
Answer: The combination of method-of-treatment with a specific patient-actuated delivery system is the second axis of protection.
- Method-of-use: exhalation-driven posterior nasal delivery for migraine.
- Device: nosepiece and substance-containing unit (plus mouthpiece in device claim 39) configured to create bi-directional exhalation flow via velum closure.
Which companies are likely to be relevant in licensing or challenges?
Answer: Not enough information is provided to identify the operating companies for the relevant intranasal sumatriptan powder product(s), nor to link US 9,649,456 to specific Orange Book-listed sponsors.
Key Takeaways
- Core innovation: exhalation-driven bi-directional airflow entrainment to deliver powdered sumatriptan to the posterior nasal cavity, coupled to velum closure via a mouthpiece-nosepiece fluid pathway.
- Composition constraint is central: claim 1 requires powder that consists essentially of sumatriptan succinate with no introduced excipients/adjuvants.
- Physical property constraints are meaningful: untapped bulk density 0.3–0.5 g/mL and PSD thresholds are explicit infringement gates.
- Design-around routes: change powder composition (introduce permitted excipients), move PSD/bulk density outside specified bands, or alter the airflow generation architecture so it is not bi-directional exhalation/velum-closure driven.
- Enforcement leverage: narrow conjunctive limitations can yield clear non-infringement if any one element is missing, but direct infringement is plausible if an accused product matches both the device mechanism and the powder spec.
FAQs
1) Does US 9,649,456 cover sumatriptan base or only sumatriptan succinate?
The claim set is anchored on sumatriptan succinate in the core excipient-free “consists essentially of” limitation in claim 1, while later dependent claim language includes “sumatriptan base or sumatriptan succinate” in recast claims.
2) Are the density and particle-size limits required for device infringement too?
Yes. The device claims include powder bulk density and particle size distribution parameters as claim limitations.
3) If a product uses a similar nosepiece but a different airflow source, is it covered?
Coverage in the key framework depends on exhalation through a mouthpiece causing velum closure and producing bi-directional flow; a different airflow source may avoid the configured “exhalation/bi-directional” limitations.
4) What is the practical meaning of “consists essentially of” here?
It is aimed at powder composition restriction, limiting introduced excipients/adjuvants. Products adding carriers or adjuvants face non-infringement arguments.
5) Do the PK and nasal absorption/BA ratio limitations affect patent scope in practice?
They appear in dependent claims (e.g., Tmax/Cmax and nasal absorption fraction vs total BA ratios), so they add narrower performance constraints for those dependent claim paths rather than the full independent claim 1 scope.
References
- United States Patent No. 9,649,456.
